The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

US Court Denies Preliminary Injunction Application against the FDA and Dismisses AstraZeneca's Lawsuit without Prejudice

Monday, March 26, 2012

US Court Denies Preliminary Injunction Application against the FDA and Dismisses AstraZeneca's Lawsuit without Prejudice02:20 EDT Monday, March 26, 2012 WILMINGTON, Del. (Business Wire) -- AstraZeneca (NYSE: AZN) today announced that on March 23, 2012 the US District Court for the District of Columbia issued an opinion and order in AstraZeneca's lawsuit against the US Food and Drug Administration (FDA) regarding final marketing approval of generic quetiapine. The Court denied the Company's request for a preliminary injunction and dismissed the lawsuit without prejudice. Notwithstanding the Court's decision, the Company continues to believe strongly in the merits of its position and is evaluating its options. About the lawsuit and the Citizen Petitions On March 12, 2012, AstraZeneca filed a lawsuit against the FDA to overturn the FDA's denial on March 7, 2012 of the Company's Citizen Petitions with regard to SEROQUEL® (quetiapine fumarate) tablets and SEROQUEL XR® (quetiapine fumarate) extended release tablets. In its lawsuit AstraZeneca sought an injunction barring the FDA from granting final marketing approval of generic quetiapine until December 2, 2012 when regulatory exclusivity expires on important clinical trial data, or, alternatively, at least until a federal court had a meaningful opportunity to review imminent FDA action regarding the pending generic marketing applications. On September 9, 2011 AstraZeneca filed a Citizen Petition with the FDA for each of SEROQUEL and SEROQUEL XR, requesting the FDA withhold finally approving any generic quetiapine product that omits from its labeling certain warning language that FDA required AstraZeneca to include in the labeling for SEROQUEL and SEROQUEL XR. Data associated with the warning language at issue is protected by marketing exclusivity periods expiring as late as December 2, 2012. In the Citizen Petitions, AstraZeneca raised important issues regarding labeling requirements for generic copies of innovative medicines, as well as data exclusivity rights granted to innovative companies that conduct new clinical trials. About AstraZeneca AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information about AstraZeneca in the US or our AZ&Me Prescription Savings Programs, please visit: or call 1-800-AZandMe (292-6363). AstraZenecaMedia Enquiries USTony Jewell, +1-302-885-4594orJulia Walker, +1-302-885-5172orMedia EnquiriesEsra Erkal-Paler, +44 20 7604 8030orSarah Lindgreen +44, 20 7604 8033orInvestor Enquiries UKJames Ward-Lilley, +44 20 7604 8122Mobile: +44 7785 432613orKarl Hård, +44 20 7604 8123Mobile: +44 7789 654364orNicklas Westerholm, +44 20 7604 8124Mobile: +44 7585 404950orInvestor Enquiries USEd Seage, +1-302-886-4065Mobile: +1-302-373-1361orJorgen Winroth, +1-212-579-0506Mobile: +1-917-612-4043